Medline Industries Recalls One Lot of Hudson RCI AddiPak® Unit Dose Vial, 0.9% Full Normal Saline Solution

September 25, 2023

On September 20, 2023, the U.S. Food and Drug Administration (FDA) announced (https://www.fda.gov/medical-devices/medical-device-recalls/medline-industries-recalls-hudson-rci-addipak-unit-dose-vial-09-full-normal-saline-solution-due) that Medline Industries had recalled a single lot of Hudson RCI AddiPak® unit dose vial, 0.9% full normal saline solution, because it may be nonsterile. FDA identified it as a class I recall, the most serious type of recall, where usage may cause serious injuries or death.

FDA update

The recall affects 18,000 units with lot number 3B085, which were distributed in the United States from April 20–July 14, 2023. Medline Industries said (https://www.fda.gov/medical-devices/medical-device-recalls/medline-industries-recalls-hudson-rci-addipak-unit-dose-vial-09-full-normal-saline-solution-due) that the affected lot passed sterility testing; however, another lot (number 3B087) cleaned during the same cycle failed sterility testing, exposing the affected lot to potential contamination. 

Use of nonsterile saline may cause serious adverse health consequences, including difficulty breathing, general discomfort, nausea, wheezing, and infection, Medline Industries said (https://www.fda.gov/medical-devices/medical-device-recalls/medline-industries-recalls-hudson-rci-addipak-unit-dose-vial-09-full-normal-saline-solution-due). Infection can lead to life-threatening sepsis (https://www.ons.org/podcasts/episode-220-oncologic-emergencies-101-febrile-neutropenia-and-sepsis) and death. Medline Industries said (https://www.fda.gov/medical-devices/medical-device-recalls/medline-industries-recalls-hudson-rci-addipak-unit-dose-vial-09-full-normal-saline-solution-due) that it has received no reports of injuries or death associated with the recall. 

On August 4, 2023, Medline Industries requested all affected customers to:

Medline Industries also requested all distributors to:

U.S. customers with questions about the recall should contact Medline Industries’ Recall Department at 866-359-1704. Healthcare professionals and consumers should report any adverse reactions or quality problems (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm) they experienced using the product to MedWatch, FDA’s Safety Information and Adverse Event Reporting Program.


Copyright © 2023 by the Oncology Nursing Society. User has permission to print one copy for personal or unit-based educational use. Contact pubpermissions@ons.org for quantity reprints or permission to adapt, excerpt, post online, or reuse ONS Voice content for any other purpose.